Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.

Abstract

BACKGROUND:

This study examined the effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.

METHODS:

Among the Study to Understand the Natural History of HIV/AIDS in the Era of Effective therapy (SUN) participants, we identified 25 individuals (cases) who were HLA-B5701-negative and who had ≥ 2 weeks without abacavir exposure at one visit and ≥ 2 weeks with abacavir exposure at the consecutive visit while maintaining viral suppression. We identified 43 individuals (controls) similarly unexposed and exposed to tenofovir. We assessed concentrations of prothrombin fragment F(1+2), D-dimer, high-sensitivity C-reactive protein, interleukin-8, intercellular adhesion molecule-1, vascular adhesion molecule-1, E-selectin, P-selectin, serum amyloid A and serum amyloid P. We examined the median percentage change of these biomarkers from the unexposed to exposed state among cases and controls compared with the expected assay variability using a sign test, and compared changes among cases with controls using the Wilcoxon rank-sum test.

RESULTS:

Baseline characteristics were similar between cases and controls: median age 45 versus 46 years, 80% versus 81% male, 64% versus 63% non-Hispanic White and median CD4(+) T-cell count 538 versus 601 cells/mm(3), respectively. Mean exposure times were 65 and 15 weeks for abacavir and tenofovir, respectively. We observed no significant changes in biomarkers from the unexposed to exposed state among cases or controls compared with the expected assay variability. We found that no biomarkers were significantly increased among cases compared with controls; however, prothrombin fragment F(1+2) was significantly lower among controls (P=0.035).

CONCLUSIONS:

In virologically suppressed contemporary HIV-infected patients, abacavir exposure was not associated with increases in biomarkers associated with increased cardiovascular risk.

• Authors: Pragna Patel, Tim Bush, Turner Overton, Jason Baker, John Hammer, Erna Kojic, Lois Conley, Keith Henry, John T Brooks, SUN Study Investigators
• Journal: Antiviral therapy (Antivir Ther) Vol. 17 Issue 4 Pg. 755-61 ( 2012) ISSN: 2040-2058 [Electronic] England
• PMID: 22301072 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anti-HIV Agents
• Biomarkers
• Dideoxynucleosides
• Organophosphonates
• Tenofovir
• Adenine
• abacavir

Topics

• Adenine (administration & dosage, analogs & derivatives, therapeutic use)
• Adult
• Anti-HIV Agents (administration & dosage, adverse effects, therapeutic use)
• Biomarkers (blood)
• Cardiovascular Diseases (blood)
• Case-Control Studies
• Dideoxynucleosides (administration & dosage, adverse effects, therapeutic use)
• Female
• HIV Infections (drug therapy)
• Humans
• Male
• Middle Aged
• Organophosphonates (administration & dosage, therapeutic use)
• Risk Factors
• Tenofovir